News
Important Only
Alto Neuroscience Announces $120 Million Private Placement Financing
March 16 (Reuters) - Alto Neuroscience Inc ANRO.N:ALTO NEUROSCIENCE ANNOUNCES $120 MILLION PRIVATE PLACEMENT FINANCINGALTO NEUROSCIENCE - TO USE PROCEEDS TO SUPPORT DEVELOPMENT OF ALTO-207 IN TREATMENT RESISTANT DEPRESSIONReuters
Mon, Mar 16
Cytomx’S Varsetatug Masetecan (Epcam Probody® Adc) Continues To Demonstrate Positive Data Supporting Potential As A New Treatment Option In Late-Line Colorectal Cancer
March 16 (Reuters) - CytomX Therapeutics Inc CTMX.O:CYTOMX’S VARSETATUG MASETECAN (EPCAM PROBODY® ADC) CONTINUES TO DEMONSTRATE POSITIVE DATA SUPPORTING POTENTIAL AS A NEW TREATMENT OPTION IN LATE-LINE COLORECTAL CANCERCYTOMX THERAPEUTICS INC - PHASE 1 STUDY WITH BEVACIZUMAB INITIATED; PHASE 1B/2 CH...Reuters
Mon, Mar 16
Structure Therapeutics Reports Positive Topline Data From Phase 2 Access Ii Trial With Once-Daily Oral Small Molecule Glp-1 Receptor Agonist, Aleniglipron
March 16 (Reuters) - Structure Therapeutics Inc GPCR.O:STRUCTURE THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM PHASE 2 ACCESS II TRIAL WITH ONCE-DAILY ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST, ALENIGLIPRONSTRUCTURE THERAPEUTICS INC - ACCESS II SHOWS PLACEBO-ADJUSTED MEAN WEIGHT LOSS OF 16.3% AT ...Reuters
Mon, Mar 16
Monte Rosa Therapeutics Announces Clinical Supply Agreement To Support Phase 2 Trial Evaluating Mrt-2359 In Combination With Apalutamide For The Treatment Of Metastatic Castration-Resistant Prostate Cancer
March 16 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O:MONTE ROSA THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT TO SUPPORT PHASE 2 TRIAL EVALUATING MRT-2359 IN COMBINATION WITH APALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCERMONTE ROSA THERAPEUTICS INC - TO INITIA...Reuters
Mon, Mar 16
Redwire Awarded Prime Contract To Build First National Security Satellite For Belgian Defence, In Close Collaboration With Aerospacelab
March 16 (Reuters) - Redwire Corp RDW.N:REDWIRE AWARDED PRIME CONTRACT TO BUILD FIRST NATIONAL SECURITY SATELLITE FOR BELGIAN DEFENCE, IN CLOSE COLLABORATION WITH AEROSPACELABREDWIRE CORP - MATTEO TO BE BUILT IN BELGIUM SUPPORTING NATIONAL DEFENCE INDUSTRIAL TECHNOLOGY BASEREDWIRE CORP - CO AND AERO...Reuters
Mon, Mar 16
Nasus Pharma Announces Positive Top Line Data From Phase 2 Clinical Study Of Ns002 Achieves Significantly Superior And Faster Epinephrine Delivery Compared To Epipen® With Accelerated Speed To Therapeutic Threshold
March 16 (Reuters) - Nasus Pharma Ltd NSRX.A:NASUS PHARMA ANNOUNCES POSITIVE TOP LINE DATA FROM PHASE 2 CLINICAL STUDY OF NS002: ACHIEVES SIGNIFICANTLY SUPERIOR AND FASTER EPINEPHRINE DELIVERY COMPARED TO EPIPEN® WITH ACCELERATED SPEED TO THERAPEUTIC THRESHOLDNASUS PHARMA LTD - NS002 SHOWS FAVORABLE...Reuters
Mon, Mar 16
Eledon Announces Updated Data From Investigator-Initiated Islet Transplant Trial Of Tegoprubart In Patients With Type 1 Diabetes At Uchicago Medicine
March 16 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O:ELEDON ANNOUNCES UPDATED DATA FROM INVESTIGATOR-INITIATED ISLET TRANSPLANT TRIAL OF TEGOPRUBART IN PATIENTS WITH TYPE 1 DIABETES AT UCHICAGO MEDICINEReuters
Mon, Mar 16
Annovis Provides Corporate Updates And Reports Fiscal Year 2025 Financial Results
March 16 (Reuters) - Annovis Bio Inc ANVS.N:ANNOVIS PROVIDES CORPORATE UPDATES AND REPORTS FISCAL YEAR 2025 FINANCIAL RESULTSANNOVIS BIO INC: ESTIMATES THAT ITS CURRENT CASH AND CASH EQUIVALENTS WILL ENABLE IT TO FUND ITS OPERATIONS INTO Q3 OF 2026Reuters
Mon, Mar 16
Medicus Pharma Announces Skinject® Phase 2 Principal Investigator And Key Opinion Leader (Kol), Babar K. Rao MD, Faad, To Provide Clinical Interpretation Of Positive Data During Business Update Webcast On March 26
March 16 (Reuters) - Medicus Pharma Ltd MDCX.O:MEDICUS PHARMA ANNOUNCES SKINJECT® PHASE 2 PRINCIPAL INVESTIGATOR AND KEY OPINION LEADER (KOL), BABAR K. RAO MD, FAAD, TO PROVIDE CLINICAL INTERPRETATION OF POSITIVE DATA DURING BUSINESS UPDATE WEBCAST ON MARCH 26Reuters
Mon, Mar 16
